Neogen Corp (NEOG): Operating Income
-$21.60M
Year ended 2026-05-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-05-31 | -$21.60M | n/m | 2026-07-30, From 2025-06-01 |
| 2025-05-31 | -$1.06B | n/m | 2026-07-30, From 2024-06-01 |
| 2024-05-31 | $58.60M | +56.2% | 2026-07-30, From 2023-06-01 |
| 2023-05-31 | $37.52M | -36.0% | 2025-07-30, From 2022-06-01 |
| 2022-05-31 | $58.62M | -21.0% | 2024-07-30, From 2021-06-01 |
| 2021-05-31 | $74.17M | +9.8% | 2023-08-15, From 2020-06-01 |
| 2020-05-31 | $67.52M | -0.8% | 2022-07-27, From 2019-06-01 |
| 2019-05-31 | $68.09M | -3.0% | 2021-07-30, From 2018-06-01 |
| 2018-05-31 | $70.19M | +8.1% | 2020-07-30, From 2017-06-01 |
| 2017-05-31 | $64.94M | +15.2% | 2019-07-30, From 2016-06-01 |
| 2016-05-31 | $56.39M | +6.2% | 2018-07-27, From 2015-06-01 |
| 2015-05-31 | $53.12M | +22.4% | 2017-07-28, From 2014-06-01 |
| 2014-05-31 | $43.39M | +6.6% | 2016-07-29, From 2013-06-01 |
| 2013-05-31 | $40.71M | +20.6% | 2015-07-30, From 2012-06-01 |
| 2012-05-31 | $33.74M | -5.8% | 2014-07-30, From 2011-06-01 |
| 2011-05-31 | $35.84M | +33.3% | 2013-07-30, From 2010-06-01 |
| 2010-05-31 | $26.88M | n/a | 2012-07-30, From 2009-06-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Neogen Corp (NEOG) | 2026-05-31 | -$21.60M | n/m |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | -$387.20M | n/m |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $310.83M | -32.0% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | -$919.20M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.36B | +20.5% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$440.99M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$16.98M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $1.65M | n/m |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.91M | n/m |
Compare NEOG, MYGN, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗